Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/27/2010CA2433067C An improved method for preparation of cefuroxime axetil
04/27/2010CA2431645C Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
04/27/2010CA2427482C Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride
04/27/2010CA2422378C Pyrazole compounds useful as protein kinase inhibitors
04/27/2010CA2408649C Piperazinedione compounds
04/27/2010CA2387719C Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components
04/27/2010CA2354213C N-triazolylmethyl-piperazine compounds with neurokinin-receptor antagonist activity
04/27/2010CA2350246C Controlled delivery of active agents
04/27/2010CA2345118C Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
04/27/2010CA2338968C Glucocorticoid-selective agents
04/27/2010CA2323776C Cytokine receptor common gamma chain like
04/27/2010CA2323696C Pharmaceutical composition based on natural synthesis progesterone and oestradiol and preparation method
04/27/2010CA2323102C Monolithic tablet for controlled drug release
04/27/2010CA2321951C Dietary control of arachidonic acid metabolism
04/27/2010CA2321926C Use of rhamnolipids in a composition for the treatment of signs of aging
04/27/2010CA2321149C Antitumor agents
04/27/2010CA2311669C (benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
04/27/2010CA2310141C Use of sulphinyl benzhydryl derivatives for treating drug-induced sleepiness
04/27/2010CA2301842C Substituted benzene compounds as antiproliferative and cholesterol lowering agents
04/27/2010CA2297998C Aqueous solution for use in the treatment of degenerative or autoimmune diseases and as an immunomodulatory agent
04/27/2010CA2275657C Endoparasiticidal and ectoparasiticidal agents
04/24/2010CA2641871A1 Pharmaceutical composition for treating alcohol-induced liver injury comprising (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({[(5r)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof
04/23/2010CA2643529A1 Method and composition for enhancement of male erectile function
04/22/2010WO2010045659A1 Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
04/22/2010WO2010045656A2 Novel sglt2 inhibitor dosage forms
04/22/2010WO2010045636A1 Therapeutic compositions and methods for treating chronic kidney disease associated with a metabolic imbalance
04/22/2010WO2010045624A1 Inhibitors of mitosis for increasing apoptosis in therapy
04/22/2010WO2010045615A2 Treatment of organophosphate exposure with ocinaplon
04/22/2010WO2010045601A2 Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
04/22/2010WO2010045599A1 Pharmaceutical compositions with attenuated release of phenolic opioids
04/22/2010WO2010045584A1 Folate targeting of nucleotides
04/22/2010WO2010045582A2 Compositions and methods for treating or preventing hypoxic or ischemic injury
04/22/2010WO2010045575A2 Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders
04/22/2010WO2010045563A2 Combination therapies for the treatment of obesity
04/22/2010WO2010045558A1 Method of determining a phosphorus binder dosage for a dialysis patient
04/22/2010WO2010045542A2 Fused ring heteroaryl kinase inhibitors
04/22/2010WO2010045529A2 Combination therapies for the treatment of obesity
04/22/2010WO2010045522A2 Combination therapies for the treatment of obesity
04/22/2010WO2010045509A2 Modulation of factor 11 expression
04/22/2010WO2010045505A1 Boron-containing small molecules as anti-protozoal agents
04/22/2010WO2010045503A1 Boron-containing small molecules as anti-protozoal agents
04/22/2010WO2010045451A1 Pyrrolopyrimidine compounds
04/22/2010WO2010045435A2 Salicylic acid composition
04/22/2010WO2010045417A2 Combination therapies for the treatment of obesity
04/22/2010WO2010045416A2 Combination therapies for the treatment of obesity
04/22/2010WO2010045402A1 Trpv1 antagonists
04/22/2010WO2010045401A1 Trpv1 antagonists
04/22/2010WO2010045395A2 Curcumin analog compositions and related methods
04/22/2010WO2010045381A2 Antimicrobial agents that target bacterial vkor
04/22/2010WO2010045379A2 Pyridine non-classical cannabinoid compounds and related methods of use
04/22/2010WO2010045377A2 Pyrimidine non-classical cannabinoid compounds and related methods of use
04/22/2010WO2010045374A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
04/22/2010WO2010045371A1 Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
04/22/2010WO2010045369A2 Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells
04/22/2010WO2010045361A1 Methods of reducing small, dense ldl particles
04/22/2010WO2010045311A1 Methods of using nitrogen-containing heterocycle derivatives
04/22/2010WO2010045310A1 Method of treating thrombocytopenia
04/22/2010WO2010045309A1 Inhibitors of akt activity
04/22/2010WO2010045306A2 Azine derivatives and methods of use thereof
04/22/2010WO2010045292A2 Nanoparticle compositions comprising liquid oil cores
04/22/2010WO2010045276A2 Azabenzimidazolones
04/22/2010WO2010045265A1 Compositions and methods for treating multiple sclerosis
04/22/2010WO2010045251A2 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010WO2010045220A1 Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
04/22/2010WO2010045212A2 Nicotinic acetylcholine receptor ligands and the uses thereof
04/22/2010WO2010045209A2 Methods of treating pulmonary disorders with liposomal amikacin formulations
04/22/2010WO2010045199A2 Method of modulating ship activity
04/22/2010WO2010045197A1 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010WO2010045190A1 Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
04/22/2010WO2010045188A1 Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
04/22/2010WO2010045166A1 Heterocyclic benzimidazoles as trpm8 modulators
04/22/2010WO2010045017A1 Amines and sulfoxides of thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045016A1 Heterocyclyl and cycloalkyl substituted thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045015A1 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045013A1 Phenyl substituted thieno [2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045012A1 Heteroaryl and phenyl substituted thieno [2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045009A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
04/22/2010WO2010045008A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
04/22/2010WO2010045006A1 Methylene amines of thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010044981A2 Benzoquinoline inhibitors of vesicular monoamine transporter 2
04/22/2010WO2010044924A1 Novel antiviral agents for enveloped viruses
04/22/2010WO2010044885A2 Soluble mtor complexes and modulators thereof
04/22/2010WO2010044878A1 Methods and compositions for improving cognitive function
04/22/2010WO2010044842A1 Tamper resistant oral dosage forms containing an embolizing agent
04/22/2010WO2010044753A1 Novel benzylidene-indolinone and their medical and diagnostic uses
04/22/2010WO2010044743A1 Novel thiophene compounds for use in theraphy
04/22/2010WO2010044686A1 Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein
04/22/2010WO2010044685A1 Nitrophenyl mustard alcohols, their corresponding phosphates and their use as targeted cytotoxic agents
04/22/2010WO2010044681A1 A medicinal product and treatment
04/22/2010WO2010044679A1 Anti-infective formulation and methods of use
04/22/2010WO2010044637A2 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
04/22/2010WO2010044585A2 Piperidine compounds, pharmaceutical composition comprising the same and its use
04/22/2010WO2010044485A1 Alpha helix mimetics in the treatment of cancer
04/22/2010WO2010044474A1 Therapeutic agent for hepatitis c
04/22/2010WO2010044441A1 Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
04/22/2010WO2010044411A1 Phenylisonicotinic acid derivative and use thereof for medical purposes
04/22/2010WO2010044410A1 Biaryl isonicotinic acid derivative and medical application of same
04/22/2010WO2010044405A1 Fused-ring derivative and medical application of same
04/22/2010WO2010044404A1 Fused heterocyclic derivative and use thereof for medical purposes
04/22/2010WO2010044403A1 5-membered heteroaryl derivative and use thereof for medical purposes
1 ... 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 ... 7860